In summary, the combined biomarker panel comprising GAL-8, ITGβ-1, and HIF-1α demonstrated excellent diagnostic performance with an AUC of 0.959, 85% sensitivity and 94% specificity at the optimal threshold, highlighting its potential utility in distinguishing glioma patients from healthy individuals. The gene discussed is HIF1A; the disease is central nervous system cancer.